Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Virologic characterization of primary human immunodeficiency virus type 1 infection in a health care worker following needlestick injury.

Pratt RD, Shapiro JF, McKinney N, Kwok S, Spector SA.

J Infect Dis. 1995 Sep;172(3):851-4.

PMID:
7658081
2.

Viral load, viral phenotype modification, zidovudine susceptibility and reverse transcriptase mutations during the first 6 months of zidovudine monotherapy in HIV-1-infected people.

Rusconi S, De Pasquale MP, Mainini F, Bulgheroni E, Kurtagic S, Gori A, Violin M, Zanchetta N, Moroni M, Balotta C, Galli M.

Antivir Ther. 1996 Dec;1(4):211-9.

PMID:
11324823
3.

The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course?

Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, Koot M, Schuitemaker H, Goudsmit J.

Virology. 1994 Oct;204(1):223-33.

PMID:
7916514
4.

Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype.

Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K.

J Pediatr. 1995 Jun;126(6):865-71.

PMID:
7776085
5.

Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.

Molina JM, Ferchal F, Chevret S, Barateau V, Poirot C, Morinet F, Modai J.

AIDS. 1994 Jan;8(1):27-33.

PMID:
7912084
6.

Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.

Relimpio F, Rey C, Pineda JA, Leal M, Caruz A, Sánchez-Quijano A, Lissen E.

Antivir Ther. 1997 Apr;2(2):99-104.

PMID:
11322281
7.

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

Ann Intern Med. 1997 Jun 15;126(12):929-38.

PMID:
9182469
8.

Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children.

Balotta C, Colombo MC, Colucci G, Viganò A, Riva C, Papagno L, Violin M, Crupi L, Bricalli D, Salvaggio A, Moroni M, Principi N, Galli M.

Pediatr Infect Dis J. 1997 Feb;16(2):205-11.

PMID:
9041602
9.
10.

Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection.

Muñoz-Fernández MA, Obregón E, Navarro J, Börner C, Gurbindo MD, Sampelayo TH, Fernández-Cruz E.

Pediatr Res. 1996 Oct;40(4):597-602.

PMID:
8888289
11.

Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome.

Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J.

AIDS. 1996 Feb;10(2):167-73.

PMID:
8838704
12.

Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction.

Piatak M Jr, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD.

AIDS. 1993 Nov;7 Suppl 2:S65-71.

PMID:
7909227
13.

Predictors for non- and slow progression in human immunodeficiency virus (HIV) type 1 infection: low viral RNA copy numbers in serum and maintenance of high HIV-1 p24-specific but not V3-specific antibody levels.

Hogervorst E, Jurriaans S, de Wolf F, van Wijk A, Wiersma A, Valk M, Roos M, van Gemen B, Coutinho R, Miedema F, et al.

J Infect Dis. 1995 Apr;171(4):811-21.

PMID:
7706807
14.

Primary subtype C HIV-1 infection in Harare, Zimbabwe.

Tien PC, Chiu T, Latif A, Ray S, Batra M, Contag CH, Zejena L, Mbizvo M, Delwart EL, Mullins JI, Katzenstein DA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Feb 1;20(2):147-53.

PMID:
10048901
15.

Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.

Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.

Antivir Ther. 1996 Dec;1(4):220-4.

PMID:
11324824
16.
18.

Effect of the HIV-1 syncytium-inducing phenotype on disease stage in vertically-infected children.

Fitzgibbon JE, Gaur S, Gavai M, Gregory P, Frenkel LD, John JF Jr.

J Med Virol. 1998 May;55(1):56-63.

PMID:
9580887
19.

HIV-1 viraemia changes in patients with and without syncytium-inducing phenotype treated with nucleoside analogues: a case-control study.

Leal M, Torres Y, Medrano FJ, Rey C, Caruz A, Sánchez-Quijano A, Lissen E.

Eur J Clin Invest. 1996 Oct;26(10):923-8.

PMID:
8911867
20.

Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team.

Fiscus SA, Hughes MD, Lathey JL, Pi T, Jackson B, Rasheed S, Elbeik T, Reichman R, Japour A, Byington R, Scott W, Griffith BP, Katzenstein DA, Hammer SM.

J Infect Dis. 1998 Mar;177(3):625-33.

PMID:
9498441

Supplemental Content

Support Center